Effects of Nutritional Ingredients on Muscle Health and Recovery Following a Short Bout of Exhaustive Exercise in Older Adults
This is a prospective, randomized, placebo controlled, double-blinded study to evaluate the efficacy of a combination of nutritional ingredients on muscle health and recovery from a short bout of exhaustive exercise in healthy older adults.
High Calorie and High Protein Diabetes-specific Oral Nutritional Supplement in Type 2 Diabetes Subjects With or at Risk of Malnutrition in Real-life Setting: A Post-marketing Observational Study (PMO)
This multicenter, prospective study will evaluate the use of a nutritional support program including an oral diabetes-specific nutritional supplement consumed twice a day on the nutritional status of patients with T2D with or at risk of malnutrition.
Snacks constitute almost a quarter of a day's calories in U.S. adults and account for about one-third of daily added sugar, a new study suggests. Researchers analyzing data from surveys of over 20,000 people found that Americans averaged about 400 to 500 calories in snacks a day -- often more than what they consumed at breakfast -- that offered little nutritional value.
Snacks constitute almost a quarter of a day's calories in U.S. adults and account for about one-third of daily added sugar, a new study suggests.
Researchers analyzing data from surveys of over 20,000 people found that Americans averaged about 400 to 500 calories in snacks a day - often more than what they consumed at breakfast - that offered little nutritional value.
Though dietitians are very aware of Americans' propensity to snack, "the magnitude of the impact isn't realized until you actually look at it," said senior study author Christopher Taylor, professor of medical dietetics in the School of Health and Rehabilitation Sciences at The Ohio State University.
"Snacks are contributing a meal's worth of intake to what we eat without it actually being a meal," Taylor said. "You know what dinner is going to be: a protein, a side dish or two. But if you eat a meal of what you eat for snacks, it becomes a completely different scenario of, generally, carbohydrates, sugars, not much protein, not much fruit, not a vegetable. So it's not a fully well-rounded meal."
Survey participants who were controlling their type 2 diabetes ate fewer sugary foods and snacked less overall than participants without diabetes and those whose blood sugar levels indicated they were prediabetic.
"Diabetes education looks like it's working, but we might need to bump education back to people who are at risk for diabetes and even to people with normal blood glucose levels to start improving dietary behaviors before people develop chronic disease," Taylor said.
The study was published recently in PLOS Global Public Health.
Researchers analyzed data from 23,708 U.S. adults over 30 years of age who had participated from 2005 to 2016 in the National Health and Nutrition Examination Survey. The survey collects 24-hour dietary recalls from each participant - detailing not just what, but when, all food was consumed.
Respondents were categorized according to their HbA1c level, a measure of glucose control, into four groups: nondiabetes, prediabetes, controlled diabetes and poorly controlled diabetes.
Among the whole survey sample, snacks accounted for between 19.5% and 22.4% of total energy intake - while contributing very little nutritional quality.
In descending order of proportion, snacks consisted of convenience foods high in carbohydrates and fats, sweets, alcoholic beverages, non-alcoholic drinks that include sugar-sweetened beverages, protein, milk and dairy, fruits, grains and, lagging far behind, vegetables.
Noting that capturing 24 hours of food consumption doesn't necessary reflect how people usually eat, "it gives us a really good snapshot of a large number of people," Taylor said. "And that can help us understand what's going on, where nutritional gaps might be and the education we can provide."
Finding that people with diabetes had healthier snacking habits was an indicator that dietary education is beneficial to people with the disease. But it's information that just about everyone can use, Taylor said - and it's about more than just cutting back on sugar and carbs.
"We need to go from just less added sugar to healthier snacking patterns," he said. "We've gotten to a point of demonizing individual foods, but we have to look at the total picture. Removing added sugars won't automatically make the vitamin C, vitamin D, phosphorus and iron better. And if we take out refined grains, we lose nutrients that come with fortification.
"When you take something out, you have to put something back in, and the substitution becomes just as important as the removal."
And so, rather than offering tips on what foods to snack on, Taylor emphasizes looking at a day's total dietary picture and seeing whether snacks will fulfill our nutritional needs.
"Especially during the holidays, it's all about the environment and what you have available, and planning accordingly. And it's about shopping behavior: What do we have in the home?" he said.
"We think about what we're going to pack for lunch and cook for dinner. But we don't plan that way for our snacks. So then you're at the mercy of what's available in your environment."
This work was supported by Abbott Nutrition and Ohio State. Co-authors included Kristen Heitman, Owen Kelly, Stephanie Fanelli and Jessica Krok-Schoen of Ohio State and Sara Thomas and Menghua Luo of Abbott Nutrition.
Rabaut brings over a decade of marketing and brand management experience to North America's largest fertility services provider
HOUSTON, Nov. 8, 2023 /PRNewswire/ -- Inception Fertility
™ (Inception), the largest provider of comprehensive fertility services across North America, announces today the appointment of Lindsey Rabaut as its new Chief Marketing Officer (CMO).
An accomplished CMO, Rabaut has over 12 years of marketing and brand management experience within Fortune 100 and private equity-backed companies, specializing in consumer segmentation, portfolio mix, digital and shopper marketing, and full-funnel attribution. She has a proven track record of success across grocery and e-commerce sectors, including personal care, baby care, pet food, and high-end fashion.
As CMO at Inception, Rabaut will lead the organization's expansive marketing and communications efforts, including executing omnichannel and go-to-market initiatives, driving brand awareness, and leading public relations efforts. This includes promoting those companies within Inception's ecosystem, which touch every part of the fertility journey, including The Prelude Network®, the fastest-growing network of fertility clinics and largest provider of comprehensive fertility services in North America; Pathways Fertility, clinics that provide affordable, individualized and high-quality care; MyEggBank®, one of the largest frozen donor egg banks in North America; BUNDL Fertility™, a multi-cycle fertility service bundling program; HavenCryo™, a long-term reproductive preservation and storage solution provider and NutraBloom®, a premium lifestyle brand with expertly formulated supplements to support individuals' health and wellness goals for preconception and beyond.
"As the field of fertility medicine expands, so does Inception, and through effective marketing and communication strategies, we can deliver key educational messages and introduce new products and service line offerings that will enhance the fertility journey for every aspiring parent," says TJ Farnsworth, CEO and Founder of Inception. "We are excited to welcome Lindsey into the Inception family and look forward to the contributions she will make to amplify our strong position within the industry."
Before joining Inception, Rabaut served as the CMO of "I and love and you" (ILY), where she created branding, portfolio, and marketing strategies that solidified ILY as one of the fastest-growing brands in the ultra-premium pet space. Rabaut's experience in women's health and baby commerce includes leadership roles at Abbott Nutrition, where she served as a Senior Brand Manager for its Similac Marketing division, and at Procter & Gamble, where she was a Brand Manager for the company's Always Pads Marketing team.
According to Rabaut, these experiences have given her consumer insight and knowledge into Inception's customer base. "I deeply understand the needs and concerns of individuals who aspire to have a baby but either have to delay parenthood or need reproductive assistance to build their families," says Rabaut. "It's an honor to use my experience and diverse marketing background to elevate the conversation around fertility and highlight Inception's commitment to providing each patient with accessibility to premium services and products and compassionate care. I'm excited to help every patient realize their dream of having a family."
Rabaut received a Master of Business Administration in Marketing from the Kelley School of Business at Indiana University and a Bachelor of Fine Arts from the College Conservatory of Music from the University of Cincinnati.
To learn more about Inception and its leadership, please visit .
About Inception Fertility™
Inception Fertility™ (Inception) is a family of fertility brands committed to helping patients build their own families. Built by patients for patients, Inception's purpose is to achieve the highest bar in experience, science and medicine in an effort to enhance each patient's experience and achieve better outcomes.
Inception's medical experts are leading pioneers in fertility care. Our doctors are some of the first to use breakthrough assisted reproductive technologies (ART) – including in vitro fertilization (IVF), preimplantation genetic testing (PGT) and fertility preservation services – and they continue to lead the industry by building on these technologies by through development, research and thought leadership.
Through its growing family of national organizations – which includes The Prelude Network®, the fastest-growing network of fertility clinics and largest provider of comprehensive fertility services in North America; Pathways Fertility, clinics that provide affordable, individualized and high quality care; MyEggBank®, one of the largest frozen donor egg banks in North America; BUNDL Fertility™, a multi-cycle fertility service bundling program; HavenCryo™, a long-term reproductive preservation and storage solution provider and NutraBloom®, a premium lifestyle brand with expertly formulated supplements to support individuals' health and wellness goals for preconception – Inception is working to deliver on its promise to push the envelope of what is possible for exceeding patient expectations.
SOURCE Inception Fertility
Warning Letters Issued to Two Companies for Illegally Selling Probiotic Products to Treat Diseases in Preterm Infants
SILVER SPRING, Md., Oct. 26, 2023 /PRNewswire/ -- As part of the U.S. Food and Drug Administration's commitment to protecting public health, the agency is advising the public, including healthcare providers, of the possible risks that products containing live bacteria or yeast, which are commonly called probiotics, pose to preterm infants in hospital settings. The agency recently sent a letter to healthcare providers warning them about this topic and has issued two warning letters to companies for illegally selling their products for use in treating or preventing certain diseases in preterm infants.
Probiotic products contain live organisms such as bacteria or yeast and are commonly marketed as foods, including as dietary supplements. The FDA is concerned as these products can be dangerous for preterm infants and are being illegally sold to treat or prevent diseases in preterm infants in hospital settings, such as to reduce the risk of necrotizing enterocolitis. Preterm infants who are administered a probiotic product are at risk of invasive, potentially fatal disease, or infection, caused by the bacteria or yeast contained in the probiotics.
The FDA is aware that certain probiotic products used in hospital settings to prevent necrotizing enterocolitis have contributed to invasive disease, including one infant death in 2023, and have been associated with more than two dozen other reported adverse events in the United States since 2018. The agency is also concerned about and is investigating reports that these products may have contributed to additional adverse events, including death, and is working to obtain the proper evidence and medical records, where possible. Any death or adverse event in an infant following the use of a probiotic product is very concerning, and the FDA is actively working with healthcare providers to better understand the link between the probiotic products used and the adverse events in preterm infants reported by these institutions.
Importantly, the FDA has not approved any probiotic product for use as a drug or biological product in infants of any age. Unapproved, unlicensed probiotics that are used to treat or prevent a disease or condition in preterm infants have not undergone the agency's thorough premarket evaluation for safety and effectiveness. Further, they have not been evaluated for compliance with the agency's rigorous manufacturing and testing standards for drugs and biological products, including testing for other organisms. For these products to be lawfully marketed as drugs and biological products, the FDA requires approval of a Biologics License Application to ensure they have been appropriately evaluated. In the absence of an approved product, healthcare providers who administer products containing live bacteria or yeast to treat, mitigate, cure or prevent a disease or condition are required to submit an Investigational New Drug application to the agency to ensure the investigational use of an unapproved product is conducted with the appropriate safeguards.
"Adverse events in any infant following the use of a probiotic are a concern to the FDA. We especially want to make clear that products containing live microorganisms may present serious risks to preterm infants
in hospital settings," said Peter Marks, M.D., Ph.D., director of the FDA's Center for Biologics Evaluation and Research. "With today's message, we want to warn parents, caregivers and healthcare providers that if these products are used for the prevention or treatment of disease, they have not undergone the agency's rigorous premarket process to evaluate their safety, effectiveness and quality for these medical uses."
The agency is committed to ensuring that any violations and safety issues presented by these products are addressed by their manufacturers. The agency issued a warning letter to Abbott Laboratories on Oct. 24, 2023, for its product, Similac Probiotic Tri-Blend, which contains B. infantis (Bb-02), S. thermophilus (TH-4) and B. lactis (BB-12). Of note, this product is not an infant formula and is not related to the previous issues the agency has noted with powdered infant formula manufactured by Abbott Nutrition. Abbott has agreed to discontinue sales of its Similac Probiotic Tri-Blend product and is working with the FDA to take additional corrective actions.
The warning letter notes the company sells the probiotic product for use in hospital settings for preterm infants. Based on the intended uses on the company's websites and Abbott's marketing materials, the product is an unapproved new drug and an unlicensed biological product being sold in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act) and the Public Health Service Act. Additionally, the product is an adulterated dietary supplement under the FD&C Act because, when intended for consumption by preterm infants, the Bb-02 and TH-4 ingredients have not met the applicable safety requirements.
The agency also recently issued a warning letter to Infinant Health, Inc (formerly Evolve BioSystems Inc.) regarding its probiotic product, Evivo with MCT Oil, an unapproved and unlicensed product sold for use in treating or preventing disease in preterm infants, in violation of the FD&C Act and the Public Health Service Act. The product was intended to be added to food for preterm infants and as such was also found to be an adulterated food under the FD&C Act. This product has since been voluntarily recalled and is no longer available in the U.S.
Protecting public health, especially of the most vulnerable populations such as preterm infants, is one of the highest priorities for the FDA," said Jim Jones,
the FDA's Deputy Commissioner for Human Foods.
"We are encouraging all involved in the care of preterm infants, including parents, caregivers and healthcare providers, to be aware of the possible risks associated with the administration of probiotic products to preterm infants in hospital settings. The FDA continues to investigate these incidents and is committed to using our available resources and authorities to identify and address potentially unsafe products in the market."
The FDA understands there are conflicting data in the literature on the safety and effectiveness of probiotics for the prevention of necrotizing enterocolitis, and that the study of the use of probiotics has been complicated by several factors, including the use of different probiotics in different trials. Because of the potential for harm posed by these products in highly vulnerable individuals, such as preterm infants, the agency urges the industry, clinical and research funding communities to focus on high quality clinical trials with products meeting quality criteria to provide definitive evidence to inform the use of these products by healthcare providers and, where appropriate, to support applications for drugs and biological products for use in infants of any age.
The agency continues to carefully review and investigate adverse event reports for probiotics. To inform the agency's surveillance efforts, and to better understand these issues to help protect public health, the FDA encourages healthcare providers and caregivers to report adverse events following use of probiotics to the manufacturer, the FDA's MedWatch program and CFSAN's Adverse Event Reporting System. Caregivers may also speak with their healthcare provider regarding concerns or questions with these products.
Dear Healthcare Provider Letter: Warning Regarding Use of Probiotics in Preterm Infants
Warning Letter: Abbott Laboratories
Warning Letter: Infinant Health, Inc formerly Evolve Biosystems Inc.
Media Contact: Carly (Kempler) Pflaum, 240-672-8872; Courtney Rhodes, 202-281-5237
Consumer Inquiries: Email, 888-INFO-FDA
The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, radiation-emitting electronic products, and for regulating tobacco products.
SOURCE U.S. Food and Drug Administration